202 related articles for article (PubMed ID: 33505152)
21. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
22. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
[TBL] [Abstract][Full Text] [Related]
23. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
Petroff D; Blank V; Newsome PN; Shalimar ; Voican CS; Thiele M; de Lédinghen V; Baumeler S; Chan WK; Perlemuter G; Cardoso AC; Aggarwal S; Sasso M; Eddowes PJ; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Cobbold JF; Naveau S; Lupsor-Platon M; Mueller S; Krag A; Irles-Depe M; Semela D; Wong GL; Wong VW; Villela-Nogueira CA; Garg H; Chazouillères O; Wiegand J; Karlas T
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):185-198. PubMed ID: 33460567
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease.
Kuroda H; Abe T; Fujiwara Y; Nagasawa T; Takikawa Y
J Med Ultrason (2001); 2021 Oct; 48(4):471-480. PubMed ID: 34415481
[TBL] [Abstract][Full Text] [Related]
25. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Qu Y; Song YY; Chen CW; Fu QC; Shi JP; Xu Y; Xie Q; Yang YF; Zhou YJ; Li LP; Xu MY; Cai XB; Zhang QD; Yu H; Fan JG; Lu LG
Clin Transl Gastroenterol; 2021 Apr; 12(4):e00323. PubMed ID: 33848277
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients.
Wang M; Tang S; Li G; Huang Z; Mo S; Yang K; Chen J; Du B; Xu J; Ding Z; Dong F
BMC Gastroenterol; 2024 Feb; 24(1):81. PubMed ID: 38395765
[TBL] [Abstract][Full Text] [Related]
29. Volumetric Liver Fat Fraction Determines Grade of Steatosis More Accurately Than Controlled Attenuation Parameter in Patients With Nonalcoholic Fatty Liver Disease.
Harry S; Lai LL; Nik Mustapha NR; Abdul Aziz YF; Vijayananthan A; Rahmat K; Mahadeva S; Chan WK
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):945-953.e2. PubMed ID: 31442603
[TBL] [Abstract][Full Text] [Related]
30. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.
Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
Dig Dis Sci; 2019 Dec; 64(12):3642-3651. PubMed ID: 31209721
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease.
Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z
Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454
[TBL] [Abstract][Full Text] [Related]
32. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.
Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ
World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779
[TBL] [Abstract][Full Text] [Related]
34. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy.
Yilmaz Y; Yesil A; Gerin F; Ergelen R; Akin H; Celikel ÇA; Imeryuz N
Scand J Gastroenterol; 2014 May; 49(5):611-6. PubMed ID: 24611771
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.
Hayashi H; Kamada Y; Fujii H; Takahashi H; Oeda S; Iwaki M; Kawaguchi T; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Ultrasound Med Biol; 2023 Jul; 49(7):1658-1664. PubMed ID: 37120329
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
38. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
39. Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease.
Ahn JM; Paik YH; Min SY; Cho JY; Sohn W; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut Liver; 2016 Mar; 10(2):295-302. PubMed ID: 26347511
[TBL] [Abstract][Full Text] [Related]
40. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
